Loading
Life sciences · Journal article
Journal of Nanobiotechnology · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Although the new anticancer molecules have been developed, incidences of the off-target adverse effects, poor bioavailability and drug resistance have remained unsolvable problems towards cancer heterogeneity. These challenges require instant diagnosis, simultaneous therapy, real-time monitoring and personalized approach towards cancer management. The integration of silica and metal into hybrid ‘nanotheranostics’ has been extensively studied over the last decade and explored as anticancers. In this review, a concept of metal–silica nanocomposites as multimodal theranostic applications is comprehensively evaluated and compared. In fact, the approach of metal confinement not only affects the tunability of optical properties required for tumor treatment, but also modulates the drug loading and release. While assortment of the recent metal–silica applications involved in nano-fabrication is highlighted, the real scenario of the applications in clinical trials is also revealed. Consequently, the critical gaps in the design and quality control are addressed to provide outlooks of metal silica nanotheranostics in cancer.